YD Bio Expands Cancer Detection Lab Reach to 46 States, Boosting Commercial Validation
YDES is trading near its 52-week low of $2.137 (6.4% below the low) on elevated volume (4.0× avg).
Summary
YD Bio's affiliate, EG BioMed US, has secured clinical laboratory licenses in Rhode Island and Pennsylvania, expanding its operational footprint to 46 U.S. states, D.C., and Guam. This significant geographic expansion directly broadens patient access for their DNA methylation-based early cancer detection services. The company views this as crucial for early commercial validation and accumulating real-world molecular data. This operational progress comes after the company reported a loss per share for the 2025 fiscal year, highlighting efforts to drive commercial growth.
At the time of this announcement, YDES was trading at $2.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $163.5M. The 52-week trading range was $2.14 to $25.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.